Diabetes trials on SGLT2 and GLP1 and their effects on hypertension
Professor Peter Nilsson held a lecture on the cardiovascular effects of SGLT-2 inhibitors and GLP-1 agonists, the two new drug classes which revolutionized the treatment of type-2 diabetes at the recent Annual Congress of the European Society of Hypertension.
According to the results:
- SGLT-2 inhibitors and GLP-1 receptor agonists are mostly safe, well-proven and effective drugs to prevent CVD complications and renal impairment/ events in type 2 diabetes patients at high or medium risk.
- GLP-1 RAs are more effective than SGLT-2is to reduce bodyweight, but SGLT-2is are more effective than standard GLP-1 RAs to reduce office and ambulatory BP.
-Recent guidelines suggest using SGLT-2i and GLP1 RA more frequently in patients at high cardiovascular risk, with or without metformin.